A Phase 1/2 interventional study of Cobimetinib in Solid Tumors, sponsored by Hoffmann-La Roche. Completed at 17 sites in 7 countries. Open to participants aged 6 Months to 30 Years. Per ClinicalTrials.gov, last updated 2022-09-16.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult participants with solid tumors with known or potential kinase pathway activation for which standard therapy has proven to be ineffective or intolerable or for which no curative standard-of-care treatment options exist. The study will be conducted in two stages: a dose-escalation stage and an expansion stage at the recommended dose.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Central nervous system gliomas, including high- and low-grade gliomas, and diffuse intrinsic pontine glioma (DIPG) Embryonal rhabdomyosarcoma and other non-rhabdomyosarcoma soft tissue sarcomas Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor Rhabdoid tumors, including atypical teratoid/rhabdoid tumor (ATRT) NF1-associated tumor (including plexiform neurofibroma), schwannoma, or RASopathy-associated tumor that in the judgment of the investigator is life threatening, results in severe symptoms (including severe pain), or is in close proximity to vital structures
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
Drug: Cobimetinib
Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Also known as: RO5514041, GDC-0973, XL-518
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.
Time frame: Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)
Percentage of Participants With Adverse Events (AEs), Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.
Time frame: Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months)
Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib
A prior dose level was defined as an MTD/MAD if at a certain dose level, there were greater than or equal to (\>=) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).
Time frame: Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)
Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I)
Tumor assessment was performed using mINRC for Participants with Neuroblastoma.
Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II)
Tumor assessment was performed using Response Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)
Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.
Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)
Tumor assessment will be performed using RANO criteria for LGG.
Time frame: Baseline up to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)
Tumor assessment was performed using mINRC for Participants with Neuroblastoma.
Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II)
Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I)
Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.
Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II)
Tumor assessment was performed using RANO criteria for Participants with LGG.
Time frame: From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Recommended Phase II Dose (RP2D) of Cobimetinib
A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).
Time frame: Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)
Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
Time frame: From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II)
Tumor assessment was performed using RANO criteria for Participants with LGG.
Time frame: From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)
Overall Survival (OS) for Participants With Neuroblastoma (Phase I)
OS was defined as the time from initiation of study drug to death from any cause.
Time frame: Baseline until death due to any cause (up to 5 years, 2 months)
OS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II)
OS was defined as the time from initiation of study drug to death from any cause. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
Time frame: Baseline until death due to any cause (up to 5 years, 2 months)
OS for Participants With All Other Tumours (Phase I)
OS was defined as the time from initiation of study drug to death from any cause.
Time frame: Baseline until death due to any cause (up to 5 years, 2 months)
Maximum Plasma Concentration Observed (Cmax) of Cobimetinib
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Cmax.
Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (predose=within 4 hours prior to dose; cycle length=28 days)
Time to Cmax (Tmax) of Cobimetinib
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Tmax.
Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.
Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
Apparent Clearance (CL/F) of Cobimetinib
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2.
Time frame: Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)
The study was conducted at 17 centers in 7 countries.
| Milestone | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 7 | 8 | 5 | 12 |
| Tumor type - neuroblastoma | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Tumor type - high-grade glioma | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Tumor type - low-grade glioma | 1 | 2 | 4 | 5 | 3 | 2 | 3 | 12 |
| Tumor type - dnet in noonan's syndrome tumor with ras/raf/mek/erk pathway activation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Tumor type - malignant peripheral nerve sheath tumor | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Tumor type - metastatic mediastinal yolksac tumor with ras/raf/mek/erk pathway activation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tumor type - non-rhabdomyosarcoma soft tissue sarcoma | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tumor type - plexiform neurofibroma | 1 | 2 | 1 | 1 | 2 | 4 | 1 | 0 |
| Tumor type - rhabdoid tumor/atrt | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 6 | 6 | 7 | 8 | 5 | 12 |
| Withdrew: Death | 2 | 2 | 1 | 2 | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Pi, physician decision; no response to trt. | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 2 | 3 | 4 | 4 | 3 | 3 | 9 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 0 | 0 | 1 | 2 | 1 |
Dose-Limiting Toxicities (DLTs) were defined as cobimetinib-related adverse events occurring within the first 28 days of each administration of cobimetinib.
| Percentage of Participants | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | 0 | 0 | 33.3 | 16.7 | 0 | 0 | 60.0 | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs.
| Percentage of Participants | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| AEs | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| SAEs | 33.3 | 33.3 | 33.3 | 33.3 | 14.3 | 25.0 | 40.0 | 41.7 |
| AESIs | 33.3 | 33.3 | 33.3 | 50.0 | 42.9 | 25.0 | 100.0 | 58.3 |
A prior dose level was defined as an MTD/MAD if at a certain dose level, there were greater than or equal to (\>=) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).
| mg/kg | Cobimetinib (Tablet) Population | Cobimetinib (Suspension) Population |
|---|---|---|
| Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Cobimetinib | 0.8 | 1 |
Tumor assessment was performed using mINRC for Participants with Neuroblastoma.
| Percentage of Participants | Neuroblastoma |
|---|---|
| Percentage of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) for Participants With Neuroblastoma (Phase I) | 0 |
Tumor assessment was performed using Response Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
| Percentage of Participants | High Grade Glioma | Low Grade Glioma |
|---|---|---|
| Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With High-Grade Glioma (HGG) (Phase I) and RECIST v1.1 for Participants With Low-Grade Glioma (LGG) (Phase I and II) | 0 | 9.4 |
Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.
| Percentage of Participants | Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation | Malignant Peripheral Nerve Sheath Tumor | Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation | Non-Rhabdomyosarcoma Soft Tissue Sarcoma | Plexiform Neurofibroma | Rhabdoid Tumor/ATRT |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I) | 0 | 0 | 0 | 0 | 0 | 0 |
Tumor assessment will be performed using RANO criteria for LGG.
| Percentage of Participants | Low Grade Glioma |
|---|---|
| Percentage of Participants With Objective Response (CR or PR) as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II) | 8.3 |
Tumor assessment was performed using mINRC for Participants with Neuroblastoma.
| Months | Neuroblastoma |
|---|---|
| Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I) | 1.3 (NA to NA) |
Tumor assessment was performed using RANO for participants with HGG and RECIST v1.1 for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
| Months | High Grade Glioma | Low Grade Glioma |
|---|---|---|
| PFS as Determined by the Investigator Using RANO Criteria for Participants With HGG (Phase I) and RECIST v1.1 for Partcipants With LGG (Phase I and II) | 1.0 (0.6 to NA) | 22.0 (9.3 to NA) |
Tumor assessment was performed using RECIST v1.1 for Participants with All Other Tumours.
| Months | Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation | Malignant Peripheral Nerve Sheath Tumor | Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation | Non-Rhabdomyosarcoma Soft Tissue Sarcoma | Plexiform Neurofibroma | Rhabdoid Tumor/ATRT |
|---|---|---|---|---|---|---|
| PFS as Determined by the Investigator Using RECIST v1.1 Criteria for Participants With All Other Tumours (Phase I) | NA (NA to NA) | 4.1 (0.7 to NA) | 1.1 (NA to NA) | 3.4 (NA to NA) | NA (18.4 to NA) | 0.5 (NA to NA) |
Tumor assessment was performed using RANO criteria for Participants with LGG.
| Months | Low Grade Glioma |
|---|---|
| PFS as Determined by the Investigator Using RANO Criteria for Participants With LGG (Phase II) | 18.4 (3.6 to NA) |
A prior dose level was defined as an RP2D if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs).
| mg/kg | Cobimetinib (Suspension) Population |
|---|---|
| Recommended Phase II Dose (RP2D) of Cobimetinib | 1 |
Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
| Months | Low Grade Glioma |
|---|---|
| Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II) | NA (NA to NA) |
Tumor assessment was performed using RANO criteria for Participants with LGG.
| Months | Low Grade Glioma |
|---|---|
| DOR as Determined by the Investigator RANO Criteria for Participants With LGG (Phase II) | NA (NA to NA) |
OS was defined as the time from initiation of study drug to death from any cause.
| Months | Neuroblastoma |
|---|---|
| Overall Survival (OS) for Participants With Neuroblastoma (Phase I) | 4.6 (NA to NA) |
OS was defined as the time from initiation of study drug to death from any cause. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.
| Months | High Grade Glioma | Low Grade Glioma |
|---|---|---|
| OS for Participants With High-Grade Glioma (HGG) (Phase I) and Low-Grade Glioma (LGG) (Phase I and II) | 1.4 (0.6 to NA) | NA (NA to NA) |
OS was defined as the time from initiation of study drug to death from any cause.
| Months | Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation | Malignant Peripheral Nerve Sheath Tumor | Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation | Non-Rhabdomyosarcoma Soft Tissue Sarcoma | Plexiform Neurofibroma | Rhabdoid Tumor/ATRT |
|---|---|---|---|---|---|---|
| OS for Participants With All Other Tumours (Phase I) | NA (NA to NA) | 5.5 (0.8 to NA) | 1.1 (NA to NA) | 6.3 (NA to NA) | NA (NA to NA) | 5.1 (NA to NA) |
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Cmax.
| ng/mL | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 62.0 ± 82.3 | 88.3 ± 102 | 144 ± 58.6 | 51.5 ± 73.4 | 67.4 ± 165 | 136 ± 80.3 | 111 ± 37.0 | 44.0 ± 69.8 |
| Cycle 1 Day 21 | 51.1 ± 74.0 | 181 ± 134 | 193 ± 35.0 | 105 ± 84.5 | 156 ± 91.2 | 179 ± 113 | 172 ± 60.3 | 116 ± 42 |
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of Tmax.
| hr | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 4 (2 to 6) | 2 (2 to 6) | 3 (2 to 4) | 4 (2 to 6) | 4 (2 to 6) | 2 (2 to 4) | 5 (2 to 6) | 4 (2 to 6) |
| Cycle 1 Day 21 | 4 (2 to 6) | 4 (2 to 6) | 2 (2 to 4) | 4 (2 to 6) | 2 (2 to 4) | 3 (2 to 6) | 4 (4 to 4) | 2 (2 to 6) |
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.
| hr*ng/mL | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 865 ± 83.0 | 1006 ± 100 | 1432 ± 50.0 | 743 ± 67.4 | 1111 ± 144 | 1627 ± 74.0 | 1567 ± 33.1 | 589 ± 79.5 |
| Cycle 1 Day 21 | 836 ± 83.5 | 2802 ± 111 | 2382 ± 38.4 | 1624 ± 80.4 | 1805 ± 109 | 2562 ± 104 | 2511 ± 104 | 1402 ± 59 |
Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2.
| L/hr | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Cobimetinib | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Collected over Baseline up until 30 days after the last dose of study drug (up to 5 years, 2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I (Tablet) Cobimetinib (0.6 mg/kg) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase I (Tablet) Cobimetinib (0.8 mg/kg) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase I (Tablet) Cobimetinib (1 mg/kg) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase I (Suspension) Cobimetinib (0.6 mg/kg) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase I (Suspension) Cobimetinib (0.8 mg/kg) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Phase I (Suspension) Cobimetinib (1 mg/kg) | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| Phase I (Suspension) Cobimetinib (1.33 mg/kg) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Phase II (Suspension) Cobimetinib (1 mg/kg) | 0/12 (0%) | 5/12 (41.7%) | 12/12 (100%) |
| Event | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| ChorioretinopathyEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/8 | 1/5 | 0/12 |
| PyrexiaGeneral disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/7 | 0/8 | 1/5 | 0/12 |
| Catheter site infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/8 | 1/5 | 0/12 |
| ParonychiaInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/8 | 1/5 | 0/12 |
| Vascular device infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/8 | 1/5 | 0/12 |
| Pericardial effusionCardiac disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/8 | 0/5 | 0/12 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/7 | 0/8 | 0/5 | 0/12 |
| InfectionInfections and infestations | 0/6 | 1/6 | 0/6 | 0/6 | 0/7 | 0/8 | 0/5 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/7 | 0/8 | 0/5 | 1/12 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/6 | 0/6 | 0/7 | 0/8 | 0/5 | 0/12 |
| Event | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/6 | 4/6 | 5/6 | 4/6 | 2/7 | 4/8 | 4/5 | 4/12 |
| VomitingGastrointestinal disorders | 1/6 | 2/6 | 4/6 | 2/6 | 2/7 | 4/8 | 2/5 | 7/12 |
| HeadacheNervous system disorders | 3/6 | 3/6 | 2/6 | 2/6 | 3/7 | 4/8 | 3/5 | 7/12 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 1/6 | 1/6 | 1/7 | 1/8 | 3/5 | 1/12 |
| Abdominal painGastrointestinal disorders | 2/6 | 3/6 | 2/6 | 1/6 | 2/7 | 1/8 | 2/5 | 3/12 |
| ConstipationGastrointestinal disorders | 3/6 | 2/6 | 3/6 | 0/6 | 0/7 | 2/8 | 1/5 | 3/12 |
| NauseaGastrointestinal disorders | 2/6 | 1/6 | 3/6 | 0/6 | 2/7 | 3/8 | 0/5 | 2/12 |
| FatigueGeneral disorders | 2/6 | 2/6 | 3/6 | 2/6 | 2/7 | 3/8 | 1/5 | 2/12 |
| Dry skinSkin and subcutaneous tissue disorders | 2/6 | 1/6 | 2/6 | 0/6 | 3/7 | 2/8 | 1/5 | 1/12 |
| PyrexiaGeneral disorders | 2/6 | 1/6 | 1/6 | 1/6 | 1/7 | 2/8 | 2/5 | 3/12 |
| Age, Continuous(Years) | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 11.8 ± 3.5 | 9.5 ± 3.3 | 9.5 ± 3.4 | 8.5 ± 1.4 | 9.7 ± 5.3 | 8.9 ± 3.1 | 10.2 ± 3.3 | 8.7 ± 7.5 | 9.5 ± 4.6 |
| Sex: Female, Male(Participants) | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 4 | 2 | 0 | 2 | 5 | 7 | 23 |
| Male | 5 | 4 | 2 | 4 | 7 | 6 | 0 | 5 | 33 |
| Race/Ethnicity, Customized(Participants) | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 4 | 11 |
| Not Hispanic or Latino | 5 | 3 | 4 | 1 | 2 | 4 | 3 | 7 | 29 |
| Not Stated | 0 | 0 | 2 | 3 | 1 | 2 | 0 | 0 | 8 |
| Unknown | 0 | 2 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Race/Ethnicity, Customized(Participants) | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 |
| Unknown | 1 | 1 | 2 | 5 | 4 | 3 | 1 | 1 | 18 |
| White | 5 | 4 | 3 | 0 | 2 | 5 | 4 | 11 | 34 |
| Tumor Type(Participants) | Phase I (Tablet) Cobimetinib (0.6 mg/kg) | Phase I (Tablet) Cobimetinib (0.8 mg/kg) | Phase I (Tablet) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (0.6 mg/kg) | Phase I (Suspension) Cobimetinib (0.8 mg/kg) | Phase I (Suspension) Cobimetinib (1 mg/kg) | Phase I (Suspension) Cobimetinib (1.33 mg/kg) | Phase II (Suspension) Cobimetinib (1 mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| High-Grade Glioma | 3 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 5 |
| Low-Grade Glioma | 1 | 2 | 4 | 5 | 3 | 2 | 3 | 12 | 32 |
| Dnet In Noonan's Syndrome Tumor With RAS/RAF/MEK/ERK Pathway Activation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Malignant Peripheral Nerve Sheath Tumor | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Metastatic Mediastinal Yolksac Tumor With RAS/RAF/MEK/ERK Pathway Activation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-Rhabdomyosarcoma Soft Tissue Sarcoma | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Plexiform Neurofibroma | 1 | 2 | 1 | 1 | 2 | 4 | 1 | 0 | 12 |
| Rhabdoid Tumor/ATRT | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Jul 2021, 62 months.
Results were first posted in Mar 2022, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib